title: Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes.
abstract: Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association between PIV-3 Ab levels and clinical outcomes in HCT recipients who acquire PIV-3 infection, are unknown. We evaluated PIV-3-specific hemagglutination inhibition Ab levels and clinical outcomes among 172 patients with PIV-3 infection following HCT. In a multivariable linear regression model, high post-transplantation Ab levels were independently associated with higher pre-transplantation recipient titer (mean difference 0.38 (95% confidence interval (CI), 0.26, 0.50), P<0.001). Significant associations between pre-HCT Ab titers in both patients and donors and occurrence of lower respiratory tract disease (LRD) after HCT were not observed. In conclusion, low pre-transplantation titers are associated with low Ab levels after HCT. The relationship between PIV-3 Ab levels and outcomes remain uncertain. Further study is needed to prospectively evaluate the dynamics of PIV-3-specific Ab responses and the relative contribution of PIV-3-specific Ab to protection from infection acquisition and progression to LRD.
authors: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors: S
authors: S
authors: Seo
authors: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors: H
authors: H
authors: Xie
authors: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
authors: R A
authors: RA
authors: Karron
authors: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
authors: B
authors: B
authors: Thumar
authors: 1] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Pediatric Infectious Diseases, Seattle Children's Hospital, Seattle, WA, USA [3] Department of Pediatrics, University of Washington, Seattle, WA, USA.
authors: J A
authors: JA
authors: Englund
authors: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors: W M
authors: WM
authors: Leisenring
authors: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors: T
authors: T
authors: Stevens-Ayers
authors: 1] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [3] Department of Medicine, University of Washington, Seattle, WA, USA.
authors: M
authors: M
authors: Boeckh
authors: 1] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [3] Pediatric Infectious Diseases, Seattle Children's Hospital, Seattle, WA, USA [4] Department of Pediatrics, University of Washington, Seattle, WA, USA.
authors: A P
authors: AP
authors: Campbell
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D000918:Antibody Specificity; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010224:Parainfluenza Virus 3, Human / Q000276:immunology*; D010253:Respirovirus Infections / Q000097:blood / Q000276:immunology*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral